Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Joshua D. Lee(New York University), Edward V. Nunes(Columbia University Irving Medical Center), Patricia Novo(New York University), Ken Bachrach(Tarzana Treatment Centers), Genie L. Bailey(Brown University), Snehal Bhatt(University of New Mexico), Sarah Farkas(New York University), Marc Fishman(Johns Hopkins University), Phoebe Gauthier(New York University), Candace C. Hodgkins(Gateway Community Services (United States)), Jacquie King(Emmes (United States)), Robert Lindblad(Emmes (United States)), David Liu(National Institute on Drug Abuse), Abigail G. Matthews(Emmes (United States)), Jeanine May(Emmes (United States)), K. Michelle Peavy(Perinatal Treatment Services), Stephen Ross(New York University), Dagmar Salazar(Emmes (United States)), Paul Schkolnik, Dikla Shmueli‐Blumberg(Emmes (United States)), Don Stablein(Emmes (United States)), Geetha Subramaniam(National Institute on Drug Abuse), John Rotrosen(New York University)
The Lancet
November 15, 2017
Cited by 695Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis